Designing a Resilient Controller for Cancer Immunotherapy: Application to a Fractional‐Order Tumour‐Immune Model
IET Systems Biology · 2025-01 · 19 (1)
DOI: 10.1049/syb2.70019 ↗Kurz gefasst
Fachartikel in der Zeitschrift IET Systems Biology, online erschienen am 05.06.2025. Verfasst von Mohamadreza Homayounzade und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mechanical Engineering Department, Fasa University, Fasa, Iran. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Models, Biological, Models, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In this paper, we propose a robust control method for the automatic treatment of targeted anti‐angiogenic molecular therapy based on multi‐input multi‐output (MIMO) nonlinear fractional and non‐fractional models using the backstepping (BS) approach. This protocol aims to eradicate tumour cells while preserving high levels of the body's natural effector cells and maintaining drug dosage within safe limits. The exponential stability of the controlled system is mathematically demonstrated using the Lyapunov theorem. Consequently, the tumour volume's convergence rate can be precisely controlled—a critical factor in cancer treatment. To fine‐tune the controller gains, a soft actor‐critic (SAC) algorithm within the framework of deep reinforcement learning (DRL) is employed, with a reward function designed based on the specific requirements of the system. Additionally, the Lyapunov theorem is used to mathematically verify the system's robustness against parametric uncertainty. Compared to state‐of‐the‐art approaches, the proposed scheme demonstrates superior long‐term performance, achieving complete tumour eradication and drug delivery convergence to zero within 50 days while preserving high effector cell levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mechanical Engineering Department, Fasa University, Fasa, Iran.
ORCID-Profile: Mohamadreza Homayounzade, Shayan Sajadian
Zitieren
APA
Homayounzade, M., & Sajadian, S. (2025). Designing a Resilient Controller for Cancer Immunotherapy: Application to a Fractional‐Order Tumour‐Immune Model. IET Systems Biology, 19(1). https://doi.org/10.1049/syb2.70019
Vancouver
Homayounzade M, Sajadian S. Designing a Resilient Controller for Cancer Immunotherapy: Application to a Fractional‐Order Tumour‐Immune Model. IET Systems Biology. 2025;19(1). doi:10.1049/syb2.70019
BibTeX
@article{Homayounzade2025,
author = {Homayounzade, Mohamadreza and Sajadian, Shayan},
title = {Designing a Resilient Controller for Cancer Immunotherapy: Application to a Fractional‐Order Tumour‐Immune Model},
journal = {IET Systems Biology},
year = {2025},
volume = {19},
number = {1},
doi = {10.1049/syb2.70019}
}
EUVIMED